Gene Therapy Sponsors Risk Additional Work With Late-Stage Manufacturing Changes
Executive Summary
Commercial scale-up during Phase III trials could create labeling issues and force additional clinical trials, US FDA officials said.
You may also be interested in...
Long-Term Postmarket Studies For Gene Therapies May Need To Be Combined, Standardized
Running multiple product-specific postmarket trials for 15 years or longer would not be cost-effective and one industry stakeholder suggests workstreams eventually could merge.
US FDA Gene Therapy Review Reorg Draws Congressional Interest
A bipartisan letter from the leaders of the House Energy and Commerce Committee’s Health Subcommittee indicates the FDA’s efforts to revamp the review structure for cell and gene therapies will be closely watched by key legislators.
US FDA Opens OTP Director Search Again
The new job notice offers a top salary, but also invites questions about the candidate pool attracted by the original solicitation.